Sector Investors News and Insights

TEVA

ETFsector.com Daily Trading Outlook

July 31, 2025 S&P futures up 1.0% in early Thursday trading, bouncing after Wednesday’s broad-based selloff that saw ~70% of the S&P 500 close lower. Laggards included energy, copper, logistics, packaging, builders, and HPCs. Outperformers were healthcare, semicap equipment, cruise lines, casual diners, casinos, tobacco, and apparel. Asian markets mostly fell with China and Hong […]

ETFsector.com Daily Trading Outlook Read More »

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

ETFsector.com Daily Trading Outlook, December 18, 2024

S&P futures up 0.3% Wednesday morning following Tuesday’s declines, where the DJIA posted its ninth consecutive loss, the longest streak since 1978. Weak breadth remains a key story, with S&P decliners outpacing advancers for the 12th straight session. Treasuries slightly weaker, dollar index flat, gold up 0.1%, Bitcoin futures down 2.4%, and WTI crude up

ETFsector.com Daily Trading Outlook, December 18, 2024 Read More »

, , , , , , , , , , , , , , , , , , ,

Insights on switching from Invega Sustenna to UZEDY for schizophrenia treatment are revealed by new data.

Teva Pharmaceuticals in the United States, a branch of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has revealed the unveiling of seven studies on its extended-release injection technology.

Insights on switching from Invega Sustenna to UZEDY for schizophrenia treatment are revealed by new data. Read More »

,
Scroll to Top

Subscribe to our Newsletter

Stay updated with the latests analysis and insights fromm etfsector.com

If you haven’t received your newsletter email, check your spam/junk folder and add us to your contacts to ensure delivery.